Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

Proteome Appoints Geoffrey Ellis As Finance Director, Loss Widens

Tue, 30th Sep 2014 09:41

LONDON (Alliance News) - Proteome Sciences PLC said Tuesday that has appointed Geoffrey Ellis as Finance Director, and posted a slightly widened pretax loss for the half-year to the end of June.

Ellis previously acted as chief financial officer of The Walt Disney Co's Network of Disney Channels in Europe, the Middle East and Africa, and managing director Disney Channel Scandinavia, Middle East and Emerging Markets.

Ellis succeeds James Malthouse, who is retiring after 20 years with the company.

Proteome posted a pretax loss of GBP2.1 million, widened from a loss of GBP1.9 million a year before, as revenue declined to GBP784,276 from GBP885,475, and administrative expenses rose slightly to GBP2.5 million from GBP2.3 million.

The company said following the growth in licensing, services and sales of its Tandem Mass Tag reagents in 2013, its core technologies had continued to strengthen in the first-half of 2014. Some contracts it was expecting were delayed, however, and the company said because of their size it is difficult to predict when they will come through.

Proteome said that whilst it is "difficult to be precise" over the timing of these revenue contributions, the scale and number of contracts in its order book is "growing steady and that performance is expected to continue in 2015."

Sales of Tandem Mass Tag reagent's rose 98% compared to the previous year. Proteome expects to see a more significant contribution from the products in the second-half, as well as continued improvement in its revenues from licences, sales and services.

Last Friday the company announced "excellent" results from in vitro toxicity tests for its two lead compounds to treat Alzheimer's disease, which it hopes will attract pharmaceutical companies to partner with Proteome on the treatments.

Shares in Proteome are trading down 8.0% at 35.18 pence Tuesday morning.

By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews

Copyright 2014 Alliance News Limited. All Rights Reserved.

Related Shares

More News
16 May 2024 12:23

IN BRIEF: Proteome Sciences promises AGM return to growth in 2024

Proteome Sciences PLC - London-based protein-focused drug development services provider - Proteome tells annual general meeting on Thursday it is "con...

16 May 2024 10:41

AIM WINNERS & LOSERS: Proteome Sciences eyes return to growth in 2024

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

26 Apr 2024 11:18

Proteome wins GBP500,000 deal to supply mass spectrometry services

(Alliance News) - Proteome Sciences PLC on Friday said it won a contract from an unnamed US biopharmaceutical company to use Proteome's mass spectrome...

26 Apr 2024 10:40

AIM WINNERS & LOSERS: Proteome Sciences rises on GBP500,000 contract

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

26 Apr 2024 09:45

Proteome Sciences secures contract win with US biopharmaceutical firm

(Sharecast News) - Contract proteomics service Proteome Sciences has secured a contract win from a US biopharmaceutical company using the company's ma...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.